gilead report sales/earn open pdf provid
busi updat investor lost wake news ceo john
milligan leav year-end fact compani deliv strong
quarter beat opco consensu expect handili see exhibit
hiv busi saw strong growth descovy-bas regimen world-wide
new hiv product biktarvi stronger expect quarter troublesom
child hcv busi demonstr sign stabil yescarta car-t also
surpris upsid late-stag pipelin nash immunolog
filgotinib continu progress set intrigu potenti
news flow could re-rat compani await visibl
note initi sinc becam ebitda-posit
revenu grown adjust ebitda addit
save live countless hiv- hcv-infect patient simplifi
treatment option legaci team transit
includ chairman previou ceo
go forward believ commerci product
trough re-rat stock could occur pipelin news flow
chart late-stag nash product selonsertib immunolog
product filgotinib demonstr good mid-stag data late-stag trial begin
read finch filgotinib stellar stellar
hiv franchis continu strong growth see
descovy-bas regimen domin therapi us eu
biktarvi launch seem hit inflect point potenti outpac
best hiv launch ever genvoya could constitut upsid model
beyond total switch come gsk dolutegravir-bas
problem-child hcv franchis stabil q/q declin
model franchis go forward remind investor minim
opex invest behind franchis constitut superb high-margin
annuiti stream go forward import car-t franchis ramp
beyond
yescarta kite pharma also strong upgrad
number us announc payment system/r
eu approv occur posit chmp vote june
yescarta key growth driver beyond
medicin area unmet medic
need gilead portfolio product
pipelin investig drug
includ treatment hiv/aid liver
inflammatori
respiratori diseas cardiovascular
analyst certif import disclosur see disclosur
initi coverag gilead perform rate
sinc launch hcv product late
share roller coaster ride
street first underappreci potenti hcv
surpris franchis declin worst-off patient
cure hcv busi stabilizng near term resurg
hiv busi growth addit kite axi-cel nash
off-set flat sales/non-gaap ep
opco model averag rel peer-group metric
believ risk/reward balanc
hcv sale declin slowli stabil
hiv busi launch taf-bas regimen bic/f/taf
make hiv solid growth busi
yescarta axi-cel launch across us eu meet
expect sale
nash franchis lead product selonsertib approv
market
cardiovascular/oth busi sale reduc
due gener competit
non-gaap oper margin declin
nhl filgotinib phase data ra
phase data nash pbc psc yescarta
year follow data phase data cle
selonsertib phase
data nash
data nash
complet list catalyst exhibit
hcv sale trough next one two year stable/up
patient diagnos treat
hiv busi outperform expect
axi-cel us/eu launch beat reduc expect provid
abl start grow margin onward
hcv busi continu declin precipit rate near
hiv busi growth minim best next two five year
axi-cel us/eu launch underperform reduc expect due
car-t side-effect manufactur reimburs concern
nash franchis gain traction clinic data
mediocr best even among nash patient fibrosi
statement million except per opcovariancenet product royalti contract total good research sell gener non-gaap oper non-gaap oper non-gaap incom expens interest non-gaap incom incom incom tax non-gaap net net loss attribut non control interest- net incom attribut dilut dilut share hcv hiv total products- selonsirtib- total total product inc
exhibit prep growth us
indicationdrugtimingmilestonehivvesatolimod phase studi hiv phase studi prephematology/oncologyyescarta axicabtagen eu aggress enrol phase follow data enrol phase indol nhl phase combo enrol phase studi line dlbcl enrol phase phase adult phase pediatr phase studi enrol phase studi anti-bcma car-t registr studi base phase enrol phase studi mage solid ind tcr target solid endpoint phase combo studi r/r cllotherremdesivir phase studi ebola survivorsnash pbc psc stellar phase data stellar phase data fxr data nash pbc psccombin interim data phase studi selonsertib and/or and/or patient advanc fibrosi due phase finch studi phase studi ankylos phase finch studi phase finch studi enrol phase select studi divers studi enrol crohn phase studi cutan lupu phase studi sjogren syndrom inc
epclusa- vosevi- hcv descovy- vemlidy- bic/ftc/taf- hiv total axi-cel- selonsirtib- total total product perform na
statement million except per product royalti contract total good research sell gener non-gaap oper non-gaap oper non-gaap incom expens interest non-gaap incom incom incom tax non-gaap net net loss attribut non control net incom attribut dilut dilut share adjust comp gross oper incom tax inc
stock price compani mention
